Evidence map›Paper›PMID 21733558›Full record

ArticleHuman pathology2011

Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3.

Xavier Badoux, Carlos Bueso-Ramos, David Harris, Ping Li, Zhiming Liu, Jan Burger, Susan O'Brien, Alessandra Ferrajoli, Michael J Keating, Zeev Estrov

Abstract read
In one paragraph

Article in Human pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.Journal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  5. Review
  6. Immunomodulatory Drugs for the Treatment of B Cell Malignancies.International journal of molecular sciences · 2021
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Targeting inflammatory pathways in chronic lymphocytic leukemia.Critical reviews in oncology/hematology · 2013
    Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xavier BadouxDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Carlos Bueso-Ramos
David Harris
Ping Li
Zhiming Liu
Jan Burger
Susan O'Brien
Alessandra Ferrajoli
Michael J Keating
Zeev Estrov
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Chronic lymphocytic leukemia bone marrow is characterized by increased angiogenesis. However, the molecular mediators of neovascularization and the biologic significance of increased endothelial cell proliferation in chronic lymphocytic leukemia require further investigation. Because signal transducer and activator of transcription 3 is constitutively activated in chronic lymphocytic leukemia, we studied the role of signal transducer and activator of transcription 3 in modulating vascular endothelial growth factor expression and the effect of vascular endothelial cells on chronic lymphocytic leukemia cells. Using chromatin immunoprecipitation, we found that anti-signal transducer and activator of transcription 3 antibodies immunoprecipitated DNA of signal transducer and activator of transcription 3, vascular endothelial growth factor, and other signal transducer and activator of transcription 3-regulated genes. In addition, signal transducer and activator of transcription 3-short interfering RNA significantly reduced messenger RNA levels of vascular endothelial growth factor in chronic lymphocytic leukemia cells, suggesting that signal transducer and activator of transcription 3 induces vascular endothelial growth factor expression in chronic lymphocytic leukemia. Remarkably, bone marrow chronic lymphocytic leukemia cells expressed high levels of vascular endothelial growth factor, and high vascular endothelial growth factor levels were detected in the plasma of patients with untreated chronic lymphocytic leukemia and correlated with white blood cell count. Chronic lymphocytic leukemia bone marrow biopsies revealed increased microvascular density and attachment of chronic lymphocytic leukemia cells to endothelial cells. Coculture of chronic lymphocytic leukemia cells and human umbilical vein endothelial cells showed a similar attachment. Furthermore, coculture studies with human umbilical vein endothelial cells showed that human umbilical vein endothelial cells protected chronic lymphocytic leukemia cells from spontaneous apoptosis by direct cell-to-cell contact as assessed by flow cytometry using annexin V. Our data suggest that constitutively activated signal transducer and activator of transcription 3 induces vascular endothelial growth factor production by chronic lymphocytic leukemia cells and that chronic lymphocytic leukemia cells derive a survival advantage from endothelial cells via cell-to-cell contact.

Indexed as

ApoptosisBone MarrowBone Marrow CellsCell CommunicationCell LineCell ProliferationChromatin ImmunoprecipitationDown-RegulationEndothelial CellsHumansHuman Umbilical Vein Endothelial CellsLeukemia, Lymphocytic, Chronic, B-CellNeovascularization, PathologicPromoter Regions, GeneticRNA, MessengerRNA, Small InterferingRNA, MessengerRNA, Small InterferingSTAT3 Transcription FactorVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID21733558
PMCPMC4085742
OpenAlexW1991966694

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.